SEC Form 4 · accession 0001193125-26-264285
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Briggs Morrison
Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 9, 2026 · 5:41 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001674416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $51.84 | Jun 5, 2026 | A | 13,000 | A | — | Jun 5, 2036 | Common Shares | 13,000 | 13,000 | D |
Explanation of responses
- F1Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.